clinical trials, phase II as topic

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer
Minsuk Kwon, Gahyun Kim, Ryul Kim, Kyu-Tae Kim, Seung Tae Kim, Simon Smith, Peter G S Mortimer, Jung Yong Hong, Arsene-Bienvenu Loembé, Itziar Irurzun-Arana, Loumpiana Koulai, Kyoung-Mee Kim, Won Ki Kang, Emma Dean, Woong-Yang Park, Jeeyun Lee

Journal for ImmunoTherapy of Cancer Jul 2022, 10 (7) e005041; DOI: 10.1136/jitc-2022-005041
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
N Nora Bennani, Hyo Jin Kim, Levi D Pederson, Pamela J Atherton, Ivana N Micallef, Gita Thanarajasingam, Grzegorz S Nowakowski, Thomas Witzig, Andrew L Feldman, Stephen M Ansell

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004984; DOI: 10.1136/jitc-2022-004984
Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
Wei Wei, Xiaohua Ban, Fan Yang, Jibin Li, Xiaqin Cheng, Rong Zhang, Xin Huang, Yongwen Huang, Qiaqia Li, Ya Qiu, Min Zheng, Xiaofeng Zhu, Jundong Li

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004338; DOI: 10.1136/jitc-2021-004338
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Jun Liu, Yang Yang, Zhichao Liu, Xiaolong Fu, Xiaoyue Cai, Hongxuan Li, Li Zhu, Yan Shen, Hong Zhang, Yifeng Sun, Hezhong Chen, Bentong Yu, Renquan Zhang, Jinchen Shao, Ming Zhang, Zhigang Li

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e004291; DOI: 10.1136/jitc-2021-004291
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
Haiping Jiang, Xiongfei Yu, Ning Li, Mei Kong, Zhimin Ma, Donghui Zhou, Weibin Wang, Haohao Wang, Haiyong Wang, Kuifeng He, Zhongqi Li, Yimin Lu, Jing Zhang, Kui Zhao, Yafei Zhang, Nong Xu, Ziran Li, Ying Liu, Yan Wang, Yisen Wang, Lisong Teng

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003635; DOI: 10.1136/jitc-2021-003635
Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
Douglas G McNeel, Jens C Eickhoff, Ellen Wargowski, Laura E Johnson, Christos E Kyriakopoulos, Hamid Emamekhoo, Joshua M Lang, Mary Jane Brennan, Glenn Liu

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e004198; DOI: 10.1136/jitc-2021-004198
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial
Dmitriy Zamarin, Sven Walderich, Aliya Holland, Qin Zhou, Alexia E Iasonos, Jean M Torrisi, Taha Merghoub, Lewis F Chesebrough, Autumn S Mcdonnell, Jacqueline M Gallagher, Yanyun Li, Travis J Hollmann, Rachel N Grisham, Courtney L Erskine, Mathew S Block, Keith L Knutson, Roisin E O’Cearbhaill, Carol Aghajanian, Jason A Konner

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000829; DOI: 10.1136/jitc-2020-000829
Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma
Brendan Curti, Marka Crittenden, Steven K Seung, Christopher B Fountain, Roxanne Payne, ShuChing Chang, Jessica Fleser, Kimberly Phillips, Ian Malkasian, Lyn B Dobrunick, Walter J Urba

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000773; DOI: 10.1136/jitc-2020-000773
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
Jieqiong Liu, Qiang Liu, Ying Li, Qian Li, Fengxi Su, Herui Yao, Shicheng Su, Quanren Wang, Liang Jin, Ying Wang, Wan Yee Lau, Zefei Jiang, Erwei Song

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000696; DOI: 10.1136/jitc-2020-000696
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Sandra P D'Angelo, Shailender Bhatia, Andrew S Brohl, Omid Hamid, Janice M Mehnert, Patrick Terheyden, Kent C Shih, Isaac Brownell, Celeste Lebbé, Karl D Lewis, Gerald P Linette, Michele Milella, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Marcis Bajars, Gülseren Güzel, Paul T Nghiem

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000674; DOI: 10.1136/jitc-2020-000674

Main menu

clinical trials, phase II as topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

clinical trials, phase II as topic

Pages